Nov 20, 2020 / 01:00PM GMT
Adrian G. Rawcliffe - Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director
Thank you everyone for joining us. I want to welcome you to Adaptimmuneâs first virtual Investor Day. A lot about the company has changed since I took over as CEO about a year ago. In the first half of 2020, we demonstrated for the first time that our SPEAR T-cells can effectively attack a range of solid tumors offering benefit and hope to people with cancer. Itâs this benefit in patients with advance solid tumors that places us at the forefront of the cell therapy revolution in cancer. From this position, we will launch the first engineered t-cell therapy for a solid tumor indication in 2 yearsâ time for people with synovial sarcoma in the United States. Weâll follow that up with additional indications starting with gastroesophageal cancers and develop a pipeline with subsequent products on the road to make cell therapy both curative and mainstream. This includes entering the clinic with our allogeneic or off the shelf platform representing we believe the future of cell therapies.
These ambitions
Adaptimmune Therapeutics PLC Corporate Analyst Meeting Transcript
Nov 20, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers